Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,001 public trials 2,038 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma

NCT01493479

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Centre Hospitalier Universitaire de Lille Lille, France
  • Centre Hospitalier Universitaire de Nantes Nantes, France
  • Centre Henri Becquerel Rouen, France
  • St George's Hospital London, United Kingdom
View Trial Details
Completed

Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma

NCT00392990

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +14 more
Locations
  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University Chicago, Illinois, United States
  • John H. Stroger Cook County Hospital Chicago, Illinois, United States
  • Rush University Medical Center Chicago, Illinois, United States
  • Loyola University Medical Center Maywood, Illinois, United States
View Trial Details
Completed

Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients

NCT01822886

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • A.O. SS. Antonio e Biagio e C. Arrigo Alessandria, Italy
  • Istituto di Ematologia ed Oncologia Medica A. Seragnoli Policlinico S. Orsola Bologna, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy
  • A.O. Universitaria Citta' Della Salute E Della Scienza Di Torino Torino, Italy
View Trial Details
Completed

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00301821

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Mayo Clinic Scottsdale Scottsdale, Arizona, United States
  • Aurora Presbyterian Hospital Aurora, Colorado, United States
  • Boulder Community Hospital Boulder, Colorado, United States
  • Penrose Cancer Center at Penrose Hospital Colorado Springs, Colorado, United States
View all 162 locations
View Trial Details
Completed

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

NCT01429025

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +27 more
Locations
  • Medical Oncology and Hematology Associates-West Des Moines Clive, Iowa, United States
  • Mercy Cancer Center-West Lakes Clive, Iowa, United States
  • Iowa Methodist Medical Center Des Moines, Iowa, United States
  • Iowa Oncology Research Association CCOP Des Moines, Iowa, United States
View all 17 locations
View Trial Details
Completed

A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)

NCT01602224

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Tucson, Arizona, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Fullerton, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Los Angeles, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Santa Barbara, California, United States
View all 57 locations
View Trial Details
Completed

Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients

NCT02164006

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin's Lymphoma, +7 more
Locations
  • TG Therapeutics Investigational Trial Site Duarte, California, United States
  • TG Therapeutics Investigational Trial Site San Diego, California, United States
  • TG Therapeutics Investigational Trial Site Sarasota, Florida, United States
  • TG Therapeutics Investigational Trial Site Detroit, Michigan, United States
View Trial Details

Related conditions